Woodstock Sterile Solutions, Inc.

Based in the US, Woodstock Sterile Solutions specializes in advanced aseptic manufacturing solutions for the pharmaceutical industry, utilizing proprietary Blow-Fill-Seal technology to minimize contamination risks in sterile product production. Founded in 1968 and headquartered in Woodstock, US, Woodstock Sterile Solutions offers pharmaceutical manufacturing services focused on aseptic processes. The company operates independently without any reported subsidiaries or parent companies. In January 2021, SK Capital acquired Catalent Inc.

’s Blow-Fill-Seal Sterile CDMO Business to enhance its operational capabilities. No specific details on founders or prior ventures are provided. Woodstock Sterile Solutions specializes in advanced aseptic pharmaceutical manufacturing solutions, primarily through its proprietary blow-fill-seal (BFS) technology. This technology allows for the rapid formation, filling, and sealing of product containers in a fully automated process, significantly reducing human intervention and the associated risks of contamination.

The company offers a range of sterile formulations, including solutions, suspensions, and emulsions, suitable for complex applications such as biologics and potent compounds. Their product offerings are utilized by healthcare companies focused on the development of ophthalmic, respiratory, and oral therapeutics. Clients include pharmaceutical manufacturers and biotech firms, primarily serving markets in North America, Europe, and Asia, where stringent regulatory compliance is paramount for product safety and efficacy. Revenue generation for Woodstock Sterile Solutions is realized through contract development and manufacturing services, where clients engage the firm on a project basis to develop and produce sterile products tailored to their specific needs.

The business model typically involves B2B transactions, where pharmaceutical companies partner with Woodstock for the manufacturing of their sterile liquid formulations, leveraging the company’s expertise in BFS technology. Transactions are structured around project agreements that outline development milestones and production schedules, with clients paying for both development and manufacturing phases. The offerings encapsulate a variety of product types, ensuring that clients receive tailored solutions that meet regulatory standards across diverse geographical markets. Woodstock Sterile Solutions aims to leverage the recent acquisition of Catalent Inc.

’s BFS Sterile CDMO Business to expand its service offerings and enhance its operational capacity. This acquisition will support the company in launching new products and expanding into new markets. The company is actively targeting further geographic areas, although specific regions and new product details are not disclosed. The acquisition, completed in January 2021, is expected to enable Woodstock Sterile Solutions to provide enhanced services to its customers.